vraylar
Phase 3
AbbVievraylar is one of 111 therapeutic programs targeting Major Depressive Disorder. It is currently in Phase 3.
3
Indications
0
Total Trials
0
Active Trials
110
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1vraylar
AbbViePhase 3
Celexa
AbbViePreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Depakote
AbbViePreclinical
Comtan
Orion Corporation, Orion PharmaPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Vivarin
HHikma Pharmaceuticals LLC
Preclinical
Rapamune
PPrism Pharmaceuticals
Preclinical
Persantine
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for vraylar. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3
- Company